(1) potential selection biases despite our rigorous screening criteria and batch effect correction; (2) limitations of the CRPGscore predictive model, which shows good but not perfect performance that could benefit from validation in larger cohorts; (3) the need for further TNNC1 functional characterization, particularly through in vivo models to better understand its impact on the tumor microenvironment; and (4) the requirement for additional preclinical and clinical validation of the five potential therapeutic compounds identified through CMap analysis. Here, TNNC1 is linked to neoplasm.